SCHEMBL7745965

SCHEMBL7745965

CCOC(=O)CCCCCn1c(CO)nc2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.58
▸ FAAH O00519 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ PTGDR2 Q9Y5Y4 4/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ TP53 P04637 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ RECQL P46063 1/20 0.52
▸ POLB P06746 2/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7741979 0.90 FAAH (0.56) SMN1; SMN2FAAHKDM4ELMNAPTGDR2
SCHEMBL22965212 0.85 PTGDR2 (0.59) FAAHKDM4ELMNAPTGDR2TP53
SCHEMBL22965246 0.85 PTGDR2 (0.54) SMN1; SMN2FAAHKDM4EPTGDR2RECQL
SCHEMBL22965231 0.84 TSHR (0.59) SMN1; SMN2FAAHKDM4ELMNAPTGDR2
SCHEMBL30536652 0.82 KDM4E (0.53) SMN1; SMN2FAAHKMT2AKDM4EPTGDR2
SCHEMBL7746512 0.82 PTGDR2 (0.48) SMN1; SMN2FAAHKDM4EPTGDR2RECQL
SCHEMBL16421862 0.82 GAA (0.59) FAAHKDM4ELMNAPTGDR2TP53
SCHEMBL9430801 0.81 PTGDR2 (0.55) SMN1; SMN2FAAHKDM4ELMNAPTGDR2
SCHEMBL3003332 0.81 PTGDR2 (0.55) SMN1; SMN2FAAHKMT2AKDM4EPTGDR2
SCHEMBL8268110 0.81 FAAH (0.54) SMN1; SMN2FAAHKDM4ELMNAPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 — — US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 — — US disclosed
Send feedback